Concretely: hair thinning · six · dulaglutide.
I am trying to do this correctly the first time rather than learn it by getting it wrong.
I have already made one mistake here that cost me a vial, so I am being deliberately careful.
What is the correct sequence, and where is the step that people usually skip?
The mechanism explains the pattern. Delayed gastric emptying plus central appetite suppression produces early satiety, and early satiety plus a slowed transit produces exactly the symptom cluster people report.
Constipation outlasts the nausea because it has two causes and only one of them resolves. Gastric emptying accommodates over weeks; total intake, and therefore stool volume and the osmotic load reaching the colon, does not recover until intake does. This is why fibre alone can make it worse — you add bulk to a system that is short of water and short of motility.
Put another way, distinguishing an injection-site nodule from an infection: a nodule is firm, non-tender or mildly tender, not warm, not expanding, and appears within a day or two. Cellulitis is warm, tender, expanding, and often accompanied by systemic features. A sterile abscess sits between the two and is fluctuant. Warmth plus expansion plus fever is the combination that stops being a forum question.
SURMOUNT-1 reported gastrointestinal events as the most frequent adverse events, mostly mild to moderate and mostly during escalation, with discontinuation for adverse events in the single digits per cent[1].
Fix the fixable causes first — fluid, electrolytes, sleep, intake — before concluding that the compound is responsible.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsSpecifically, the honest framing is that this is very common, usually self-limiting, and occasionally the presentation of something that is not self-limiting at all — and the differentiating features are specific enough to be worth knowing.
The gallbladder signal tracks the rate of weight loss more than it tracks the drug. Rapid mobilisation of adipose tissue increases biliary cholesterol saturation and reduces gallbladder motility; that combination is lithogenic whether the loss came from a drug, a very-low-energy diet or bariatric surgery. The drug contribution on top of that is present but smaller than the rate contribution.
Fatigue attribution is a subtraction problem. Take out the energy deficit, the dehydration, the electrolyte shortfall and the poor sleep, and what remains attributable to the drug in the trials was modest — placebo-arm fatigue rates were within a few points of active-arm rates in most of the programme. The corollary is that the fixable causes are usually the actual causes.
Telogen effluvium following substantial weight loss is documented independently of any pharmacotherapy, which is the cleanest argument that the rate of loss rather than the agent is the primary driver.
Write down in advance which symptoms mean stop and seek care. It is a short list and it is much easier to write when you are well.
Timing is the most useful diagnostic feature here and it is the one most often omitted from the question.
Pancreatitis red flags worth memorising rather than looking up: severe, persistent epigastric pain radiating to the back, worse lying flat and better sitting forward, with nausea and vomiting that does not settle. That combination is an urgent assessment, not a dose adjustment. An isolated lipase elevation without that picture is common and usually not pancreatitis.
Injection-site reactions are more often diluent-related than peptide-related. Benzyl alcohol sensitivity is uncommon but real, and it presents as a consistent local reaction at every site with a preserved diluent and no reaction with an unpreserved one — which is a straightforward thing to establish. Injection depth is the other common cause: intradermal placement stings and welts, subcutaneous placement usually does not.
The prescribing information for each agent lists adverse reaction frequencies against placebo in a table, and reading that table is more informative than reading a hundred anecdotes, because it has a denominator.
Most of this resolves. The point of knowing the pattern is to recognise the small fraction that does not.
edited 26 Sept 2025 by charge_state_3 — updated for the 2026 guidance change
It helps to be literal here: look at the placebo arm before concluding anything about attribution. The placebo-arm rates for most of these events are not small, because the events themselves are common in the underlying population.
Vomiting matters mostly through its consequences. Loss of gastric fluid depletes sodium, chloride and potassium, and hypokalaemia presents as exactly the fatigue and cramping people attribute to the drug. Persistent vomiting also makes a renal panel uninterpretable, because a pre-renal picture looks like renal impairment.
Pooled analyses of gallbladder-related events with GLP-1 receptor agonists find a modest increase in relative risk, with the effect larger at higher doses and longer durations — consistent with a rate-of-loss mechanism as much as a direct one[1].
One qualification — reported incidence in a monitored trial population is a lower bound on what happens in an unmonitored one, because trial participants were escalated to protocol and supported through it.
If the timing does not fit the escalation, look for another explanation before settling on the drug.
More usefully, the distinction worth making early is between a tolerability problem, which is unpleasant and self-limiting, and a clinical problem, which is neither. They present differently and the thresholds for each are worth writing down before you need them.
Early satiety is not a side effect; it is the mechanism being observable. The useful distinction is between satiety, where you stop eating without distress, and aversion, where the thought of food is unpleasant. The first is the intended effect. The second frequently precedes the dose being too high or escalated too fast.
The pooled gastrointestinal adverse-event rates across the STEP programme and the SURMOUNT programme are reported in the primary publications and in the FDA and EMA assessment reports, and the assessment reports are more useful because they give the placebo-arm rates alongside the active-arm rates in the same table.
Worth being explicit: nothing here is medical advice, and research-use-only compounds are not approved for human use.
A symptom diary with dates against dose steps answers most of these questions without anyone needing to guess.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.